Loading...
•
Dec 31, 2020
Avinger Q4 2020 Earnings Report
Avinger's Q4 2020 financial results were reported, showing sequential revenue growth and improved gross margin.
Key Takeaways
Avinger reported a 19% sequential increase in total revenue to $2.7 million, driven by a 38% sequential increase in image-guided CTO revenue from the limited launch of Tigereye. Gross margin rose to 36%, and the company ended the year with $22.2 million in cash and cash equivalents.
Revenue increased 19% sequentially to $2.7 million, the highest level in 3 years.
Image-guided CTO revenue increased 38% sequentially, driven by limited launch of the new Tigereye™ device.
Gross margin rose sequentially to 36%, reflecting increased sales activity and cost efficiency.
Opened 9 new Lumivascular accounts in the fourth quarter, bringing total new accounts for the full year to 36.
Forward Guidance
Avinger is focused on driving top-line growth through new product introductions, new account launches, and expanded utilization at existing sites. They are investing in future growth drivers, including the next generation Lightbox 3, additional new PAD catheter solutions, expansion of the field sales team, and advancement of clinical efforts.
Positive Outlook
- Full commercial launch of Tigereye in January 2021.
- Compelling patient outcomes with Tigereye's enhanced imaging, steerability, and new distal tip design.
- Strong competitive position with three next generation products launched over the past three years.
- Leaner operating cost structure.
- Strengthened balance sheet.
Challenges Ahead
- Dependency on a limited number of products.
- Resource requirements related to Pantheris, TIGEREYE and our Lightbox imaging console.
- Outcome of clinical trial results.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...